Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Fineline Cube Mar 5, 2026
Company Drug

Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Fineline Cube Mar 9, 2026
Company Drug

Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers

Fineline Cube Mar 9, 2026
Company Deals

Jiangsu Trausim Raises RMB 100M in Series A Financing for Dental Implants

Fineline Cube Nov 9, 2022

China-based Jiangsu Trausim Medical Instrument Co., Ltd, a wholly-owned subsidiary of Fulong Holdings and focused...

Company Drug

Cyramza Prescribed in China for Advanced Gastric Cancer

Fineline Cube Nov 9, 2022

Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...

Company Deals

Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization

Fineline Cube Nov 9, 2022

German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based...

Company Drug

Merck’s Keytruda Receives 10th Indication Approval in China for TNBC

Fineline Cube Nov 9, 2022

US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has...

Company Deals

Takeda Partners with CCCMHPIE to Boost Rare Disease Drug Access in China

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Japan-based Takeda Pharmaceutical Co., Ltd’s China unit...

Company Deals

Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies

Fineline Cube Nov 8, 2022

Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD...

Company

Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance

Fineline Cube Nov 8, 2022

Denmark-based biopharma Novo Nordisk A/S (NYSE: NVO) has released its Q3 2022 earnings report. The...

Company Deals

Novo Nordisk Partners with Shanghai Pharma for Smart Logistics at CIIE

Fineline Cube Nov 8, 2022

Novo Nordisk (NYSE: NVO) has announced a strategic partnership with China’s Shanghai Pharmaceuticals (HKG: 2607,...

Company Deals

SIMR Biotechnology Raises RMB 150M in Series C1 Financing Round

Fineline Cube Nov 8, 2022

China’s Shanghai SIMR Biotechnology Co., Ltd has reportedly raised RMB 150 million (USD 20.7 million)...

Company Deals Digital

PingAn Good Doctor Partners with Roche and OrigiMed at CIIE

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw China-based Ping An Healthcare and Technology Co.,...

Company Deals Digital

Organon Partners with Alibaba Health to Enhance Chronic Disease Management

Fineline Cube Nov 8, 2022

Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that...

Company Drug

Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study

Fineline Cube Nov 8, 2022

China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...

Company Deals

Organon Sponsors Retail Pharmacy Health Center at CIIE

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Organon & Co. (NYSE: OGN), a firm...

Company Deals

Sanofi Partners with China Resources Sanjiu at CIIE for Consumer Healthcare

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Sanofi’s consumer healthcare unit announce a partnership...

Company Deals

Sumitomo Dainippon Partners with Profex to Promote Antipsychotics in China

Fineline Cube Nov 8, 2022

Japan-based Sumitomo Dainippon Pharma Co., Ltd has announced a partnership with Profex, a trade company...

Company Deals

Eli Lilly Partners with AmoyDx and Burning Rock for Retevmo Companion Diagnostics

Fineline Cube Nov 7, 2022

The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a...

Company

BioNTech’s Comirnaty Gets Limited Authorization in China Amid Scholz Visit

Fineline Cube Nov 7, 2022

Germany-based mRNA specialist BioNTech (NASDAQ: BNTX) reportedly benefited from German Chancellor Olaf Scholz’s visit to...

Company

Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline

Fineline Cube Nov 7, 2022

US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health...

Company Deals

Organon Signs MOU with China’s National Health Commission at CIIE

Fineline Cube Nov 7, 2022

Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that...

Company Drug

Ascletis Pharma Presents Phase I Study Results for ASC43F at AASLD

Fineline Cube Nov 7, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) made a poster presentation detailing the abstract of a...

Posts pagination

1 … 570 571 572 … 632

Recent updates

  • Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis
  • Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets
  • Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers
  • Leads Biolabs’ Opamtistomig Enters Phase II in First-Line Esophageal Cancer – PD-L1/4-1BB Bispecific with BTD/ODD Designations
  • CSPC’s SYH2059 Inhalation Powder Wins FDA IND Approval – PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Company Drug

Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers

Company Drug

Leads Biolabs’ Opamtistomig Enters Phase II in First-Line Esophageal Cancer – PD-L1/4-1BB Bispecific with BTD/ODD Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.